Celltrion Pharm, Disease Control Agency Sign Additional Supply Contract for 'Rekkirona'
Supply of Treatments for Approximately 50,000 Patients by Q1 Next Year
Over 33,915 Doses Administered at 212 Hospitals Nationwide So Far
[Asia Economy Reporter Kim Daehyun] Celltrion Pharm has signed an additional supply contract for the COVID-19 antibody treatment 'Rekkirona' with the Korea Disease Control and Prevention Agency.
On the 27th, Celltrion Pharm announced, "We supplied about 50,000 doses of Rekkirona produced by Celltrion to designated treatment institutions nationwide in the first quarter of next year."
This is a proactive government measure to ensure a stable supply of Rekkirona in response to the rapid spread of COVID-19. Previously, on the 24th of last month, the Korea Disease Control and Prevention Agency decided to actively use the antibody treatment Rekkirona from the pre-severe stage to reduce the increasing trend of severe and critical patients and has been promoting expanded supply.
Rekkirona is the only domestic COVID-19 antibody treatment that has obtained formal product approval from the Korea Ministry of Food and Drug Safety and the European Medicines Agency (EMA). According to the Central Disease Control Headquarters' data as of December 23, it has been administered to 33,915 patients in 212 hospitals nationwide. Large-scale Phase 3 clinical trial results showed that in high-risk patients treated with Rekkirona, the incidence of severe cases decreased by 72% compared to the placebo group, and the time to clinical symptom improvement was shortened by more than 4.7 days compared to the placebo group in high-risk patients.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
A Celltrion Pharm official stated, "Since receiving conditional approval from the Ministry of Food and Drug Safety, Rekkirona has faithfully served as an antibody treatment to treat confirmed COVID-19 patients and prevent virus spread on the front lines in Korea," adding, "Now that the domestic supply volume for the first quarter of next year has been confirmed, we will do our best to help prevent the spread of COVID-19 through stable supply."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
